Comparison · NCT04425629-a37274e4
Phase 3 Cohort 1 (1.2g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 1.2g IV
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 3 Cohort 1 (1.2g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 1.2g IV. Trial comparisons, record NCT04425629-a37274e4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04425629-a37274e4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0272 | 0.0177 | 0.0416 | wilson | |
| Risk in group 2 | 0.0682 | 0.0522 | 0.0885 | wilson | |
| Risk difference, group 1 minus group 2 | -0.041 | -0.0635 | -0.0195 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.399 | 0.24 | 0.662 | log | |
| Odds ratio, group 1 over group 2 | 0.382 | 0.225 | 0.647 | log | |
| Number needed to treat, for one fewer participant with the outcome on Phase 3 Cohort 1 (1.2g IV) >= 18 than on Phase 3 Cohort 1 (Placebo) >=18 | 24.4 | 15.8 | 51.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 3 Cohort 1 (1.2g IV) >= 18 | Phase 3 Cohort 1 (1.2g IV) | 20 | 736 | OG001 |
| Group 2 | Phase 3 Cohort 1 (Placebo) >=18 | Phase 3 Cohort 1 (Placebo) | 51 | 748 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 1.2g IV
- Description
- Phase 3 Cohort 1 - Placebo vs. 1.2 g IV
- Time frame
- Through Day 29
- Population
Participants that were ≥18 years old and not pregnant at randomization, and randomized on or before 17-Jan-2021 with detectable SARS-CoV-2 RNA by RT-qPCR in nasopharyngeal swabs at randomization and at least 1 risk factor for severe COVID-19 at baseline
Source ClinicalTrials.gov
Trial
- Title
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
- NCT number
- NCT04425629
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab combination therapy
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2023-12-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04425629?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04425629-a37274e4